Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations
暂无分享,去创建一个
E. R. van den Heuvel | J. Kosterink | J. Alffenaar | T. S. van der Werf | D. Uges | L. Span | M. Rodgers | M. V. van Wanrooy | M. A. Encalada Ventura
[1] R. Arav-Boger,et al. Autoinduction of Voriconazole Metabolism in a Child with Invasive Pulmonary Aspergillosis , 2015, Pharmacotherapy.
[2] E. R. van den Heuvel,et al. Influence of Inflammation on Voriconazole Metabolism , 2015, Antimicrobial Agents and Chemotherapy.
[3] R. Shah,et al. Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine , 2015, Drug Metabolism and Disposition.
[4] H. Lipp,et al. Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients—an evidence-based approach , 2015, Annals of Hematology.
[5] D. Touw,et al. Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. , 2014, The Journal of antimicrobial chemotherapy.
[6] E. R. van den Heuvel,et al. Inflammation Is Associated with Voriconazole Trough Concentrations , 2014, Antimicrobial Agents and Chemotherapy.
[7] D. Fredricks,et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events , 2013, BMC Infectious Diseases.
[8] S. Eymard-Duvernay,et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[9] M. Xavier,et al. Voriconazole therapeutic drug monitoring: focus on safety , 2010, Expert opinion on drug safety.
[10] W. Haefeli,et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. , 2009, British journal of clinical pharmacology.
[11] J. Kosterink,et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] K. Ho,et al. An Update on C-reactive Protein for Intensivists , 2009, Anaesthesia and intensive care.
[13] J. Mehta,et al. Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation , 2009, Antimicrobial Agents and Chemotherapy.
[14] W. Haefeli,et al. CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.
[15] R. Danner,et al. Accelerated Metabolism of Voriconazole and Its Partial Reversal by Cimetidine , 2009, Antimicrobial Agents and Chemotherapy.
[16] Micheline Piquette-Miller,et al. Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer , 2008, Drug Metabolism and Disposition.
[17] R. Herbrecht,et al. Clinical pharmacokinetics of voriconazole. , 2006, International journal of antimicrobial agents.
[18] T. A. Richardson,et al. Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.
[19] F. Jamali,et al. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. , 2005, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[20] K. Renton,et al. Regulation of drug metabolism and disposition during inflammation and infection , 2005, Expert opinion on drug metabolism & toxicology.
[21] N. Wood,et al. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. , 2003, British journal of clinical pharmacology.
[22] N. Wood,et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. , 2003, British journal of clinical pharmacology.
[23] N. Wood,et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[24] D A Smith,et al. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[25] S. Clarke,et al. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.
[26] N. Wood,et al. Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.
[27] K. Renton. Alteration of drug biotransformation and elimination during infection and inflammation. , 2001, Pharmacology & therapeutics.
[28] E. Morgan. Regulation of cytochrome p450 by inflammatory mediators: why and how? , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[29] A. Gautier,et al. C-reactive protein , 2005 .
[30] B. Franke,et al. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. , 2010, Journal of Antimicrobial Chemotherapy.
[31] J. Kosterink,et al. Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC/MS/MS. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[32] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.